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1. Introduction 
In fat cells, the first evidence confirming the 
coexistence of functionally opposed (Y- and 
P-adrenergic receptors as regulatory subunits of 
adenylate cyclase [ 1] was obtained with human 
adipocytes [2]. However, it was rapidly felt that this 
concept could not be extended to the fat cells of all 
species tudied and particularly to the commonly used 
rat fat cells [3]. 
Recent studies have shown that hamster white fat 
cells have a peculiar behaviour which set them apart 
from rat adipocytes [4]. Indeed, experiments testing 
the influence of catecholamine and phentolamine on 
CAMP metabolism provided some evidence for the 
existence of a-adrenergic sensitivity in these cells, 
suggesting that hamster adipocytes may be an appro- 
priate model to study some aspects of the hormonal 
control of human fat cells [4] ; To date, however, no 
attempt has been made to directly identify the 
cr-adrenergic receptors in hamster white fat cells. 
Recently, methods measuring the binding of the 
aadrenergic antagonist [3 H] dihydroergocryptine 
[5] have been successfully used for the direct iden- 
tification of a-adrenergic receptors in different tissues 
[6-g] and cells [9]. Using these binding techniques, 
we now report, in hamster white adipocyte, the iden- 
tification of [3H] dihydroergocryptine binding sites 
which have the characteristics expected of a-adrenergic 
receptors and which appear therefore to represent the 
* To whom correspondence should be addressed 
physiologically-active hamster adipocyte a-adrenergic 
receptors. 
2. Material and methods 
2 .l . Materials 
[ 3H] Dihydroergocryptine (spec. act. 22 Ci/mmol) 
prepared by the Radiochemical Centre (Amersham) 
and stored in the dark at -2O’C in ethanol, had a 
radiochemical purity of 98% (checked by thin-layer 
chromatography [7]). Fresh stock solutions, prepared 
by adding [‘Hjdihydroergocryptine to an aqueous 
solution containing 5 mM HCl and 10% ethanol, were 
diluted 6-fold when added to the binding assay. 
Under these conditions, ethanol up to 4% in the assay 
had no effect on the specific binding of [3H]dihydro- 
ergocryptine. 
(-)-Epinephrine, (-)-norepinephrine, (-)-iso- 
proterenol (all as bitartrate) and ergotamine tartrate 
were from Sigma. Bitartrate salts of (t)epinephrine, 
(t)-norepinephrine and (t)-isoproterenol were gifts 
from Sterling Winthrop Pharmaceuticals. Phentol- 
amine methane sulfonate and phenoxybenzamine 
hydrochloride were generously supplied by Ciba-Geigy 
and Smith, Kline and French, respectively. (-)- and 
(t)-propranolol hydrochlorides were gifts from 
ICI-Pharma. 
Stock solutions of ergotamine, phentolamine and 
propranolol were freshly prepared as above for 
dihydroergocryptine. Stock solutions of phenoxy- 
benzamine prepared at 6 X 10” M in absolute 
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ethanol and diluted in 10 mM MgClz, 50 mM Tris- 
HCl, were freshly prepared before use in the binding 
assays. 
2.2.Preparation of ‘crude’adipocyte membranes 
Male golden hamsters (Charles Rivers), 95-105 g, 
were fed ad libitum before being sacrificed by decapi- 
tation. Epididymal fat pads from 1 S-20 hamsters 
were pooled and isolated fat cells prepared following 
the rapid (7 min) collagenase digestion isolation 
procedure in [lo]. Crude adipocyte membranes, 
prepared as in [ 111, were finally suspended in 10 mM 
MgClz ,50 mM Tris-HCl, resulting in a suspension 
containing 2-2.5 mg protein/ml which was used in 
the binding assays. Protein was determined according 
to [ 121 using bovine serum albumin as a standard. 
2.3. Binding assays 
Binding assays were performed, using daily- 
prepared crude membranes according to a slight 
modification of the procedure in [7]. Protein 
(300-350 pg) was usually Incubated with 15 nM 
[3H]dihydroergocryptine in total vol. 150 pl incuba- 
tion buffer (10 mM MgCla, 50 mM Tris-HCl) for 
different periods (usually 10 min) with shaking at 
37’C. Incubations were terminated by adding 5 ml 
incubation buffer, followed by a rapid vacuum filtra- 
tion of the suspension through a Whatman GFC glass. 
fiber filter. Filters were rapidly washed with two 
7.5 ml portions of buffer. Under these conditions, 
filtration and washing required less than 30 s. Filters 
were dried and added to 5 ml scintillation cocktail 
(Instagel, Packard) and counted in a Kontron MR 300 
spectrometer with an efficiency of 40%. 
Non-specific binding was determined by measuring 
the radioactivity retained on filters when incubations 
were performed in the presence of a large excess 
(10 or 100 PM) of phentolamine. All values reported 
refer to specific or receptor binding which is defined 
as total radioactivity bound minus non-specific bind- 
ing and which generally averaged 75-85% of the total 
counts bound. 
As attested by chromatographical studies, no 
degradation of [3H]dihydroergocryptine could be 
detected during the binding incubations. 
2.4. Other determinations 
The equilibrium dissociation constant, K, , for the 
242 
interaction of the binding site with each of the com- 
pounds tested for their ability to compete with 
[3H]dihydroergocryptine was calculated according to 
[ 131, from the concentrations of these agents, EC,,, 
that caused 50%inhibition of [3H] dihydroergocryptine 
binding. Cell numbers were calculated as in [ 141. 
3. Results 
3 .l . Number and affinity of binding sites 
The binding of [‘Hldihydroergocryptine to 
hamster white fat cell membranes was a saturable 
process (fig.1) with 1 .l pmol [3H] dihydroergocryptine 
bound/mg protein at saturation. Half-maximal satura- 
tion occured at -10 nM [3H]dihydroergocryptine 
providing an estimate of the K, for the interaction of 
[ 3H] dihydroergocryptine with the binding sites. 
Scatchard [ 151 analysis of these binding data suggests 
N = 132 PHOL / MC PROTEIN 
Fig.1. Specific binding of [3H]dihydroergocryptine to 
hamster adipocyte membranes as a function of [‘HI dihydro- 
ergocryptine concentration. Hamster adipocyte membranes 
(2 mg/ml) were incubated with the indicated concentrations 
of [‘Hldihydroergocryptine and specific binding was deter- 
mined as described under section 2. Each value is the mean 
of duplicate determinations from two separate xperiments. 
Inset: Scatchard plot of [ ‘H]dihydroergocryptine binding to 
hamster adipocyte membranes. The ratio (B/F) of bound 
[ “Hldihydroergocryptine to free [ “H]dihydroergocryptine 
is plotted as a function of bound ligand (pM/mg of protein). 
The slope of the plot, -l/Kd, was determined by linear 
regression analysis (correlation coefficient r = 0.97). 
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a single order of sites with K, 15 nM (fig.1, inset). 
Intercept of this plot with the abscissa provides an 
estimate of the maximal number of binding sites 
n = 1.2 pmol/mg membrane protein, i.e., a density 
of 110 000 dihydroergocryptine binding sites per cell. 
3 2. Kinesis of ~3~~dj~yd~oe~oe~pti~e bjnd~g 
The binding of L3H] d~ydroergo~rypt~e was 
rapidly reaching equilibrium within 10 min at 37°C 
(fig.2) and was reversible (fig.3) dissociation of 
[3H]dihydroergocryptine from its binding sites 
following first-order kinetics with a rate constant, 
kz, determined by linear egression analysis (r = 0.99) 
of 0.053 min-’ (data not shown). 
Since the concentration of ~y~oergocrypt~e 
(15 n&I) was much greater than the binding site 
concentration i  the association assay (1.2 nM), the 
formation of the dihydroergocryptine-receptor 
complex could be considered as a pseudo-first order 
reaction depending only on the binding site concen- 
tration. This was evidenced by the linearity of the 
plot defined by the equation: 
(data not shown) where Xeq represents he amount of 
radioligand bound at equilibrium (0.65 pmol/mg 
o” I I 1 10 15 0 
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Fig.2. Time course of [ 3H]dihydroergocryptine binding to 
hamster adipocyte membranes. ~3H]~~y~oergo~ypt~e 
(15 nM) was incubated with hamster adipocyte membranes 
for the indicated times at 37°C and specific binding was 
determined as described under section 2. Each value is the 
mean of duplicate determinations. 
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Fig.3. Reversibility of [ ‘Hldihydroergocryptine binding to 
hamster adipocyte membranes. Membranes were incubated 
with [3H]dihydroergocryptine (15 nM) at 37°C for 10 min, 
after which a Large xcess of phentolamine (100 JIM) was 
added (t = 0). The specific binding of [ jH] dihydroergo- 
cryptine was determined as a function of time as described 
under section 2. Each value is the mean of duplicate deter- 
minations. Maximum binding is defined as the amount of 
binding just prior to the addition of phentofamine at t = 0. 
protein) and X is the amount of [3H]dihydroergo- 
cryptine bound at each time t; under these conditions, 
the slope k, (pseudo-first order rate constant) deter- 
mined by linear recession analysis (r = 0.99) was 
equal to 0.30 min-’ . The second order rate constant, 
kl , computed from kl = (kob - kz) / DDE, where 
DHE is the concentration of [3H]dihydroergocryptine 
in the binding assay, was equal to 1.6 X 10’ M-r min”‘. 
The value of the ratio kz/kl = 3.2 nM, which provides 
a kinetically-derived stimate of the & of [3H]dihydro- 
ergocryptine binding sites, is comparable to the 
& (1 O-l 5 nM) derived from equilibrium studies 
(fig.1 .). 
3.3. Specificity of binding 
Adrenergic agonists competed for the [3H]dihydro- 
ergocryptine binding sites (fig.4) in the following 
order of potency: 
(-)-isoproterenol. 
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Fig.4, ~ililibition of [ ‘H]dihydroergocryptine binding by 
adrenergic agonists. Hamster adipocyte membranes were 
incubated with [ %I]dihydroergocrypfine (15 nM) and with 
increasing concen~ations of the indicated agonists. “100% 
inhibition” refers to the inhibition of specific binding by 
LOO FM phentoiamine. Each value is the mean of duplicate 
determinations from two separate xperiments. 
f-)-Epinephrine and (-~-n~repinep~~r~ne hadhigh 
affinity for ~~l~]di~lydroer~ocryptine bi ding sites, 
with respective K, 2 PM and 8 GM; (-)-isoproterenol, 
on the contrary, had very low affinity (Kd 150 FM). 
The [3H]dihydroergocryptine binding sites were 
highly stereospecific (fig.4), the concentrations of the 
(~~stereo~so~~~ers of epinephrine and ~~orep~nepl~r~ne 
required to ~~a~f-l~~ax~~llal~y inhibit the binding being, 
respectively, 15 and I4-fold higher than those of the 
corresponding (----)-stereoisomers. 
As shown in table 1, the a-adrenergic antagonists 
~i~entolamine and p~lenoxybenza~nine potently com- 
peted for the binding sites, with respective K,j 50 nM 
and 90 nM, in good agreement with their reported K, 
values as cu-adrenergic antagonist in other tissues [ I6] _ 
In contrast, the ~-adrenergic anta~ollist (-~-propranolo1 
competed for the f~H]dihydroergocryptine binding 
sites only at very high concentrations (Kd iOQ PM>, 
Finally, dopamine and serotonin were also found 
to be very weak competitors for the [ 3H] dihydro- 
ergocryptine binding sites (Kd SO MM and 150 PM, 
respectively), whereas the potent a-adrenergic ergot 
Table 1 
Inhibition of [ 3H]dihydroergocryptine binding by different 
adrenergic and non-adr~n~r~ic agents 
Compounds Kd fnMf 
(-)-Epinephrine 2000 
(-)-Norepinephrine 8000 
(+)-Epinephrine 30 000 
(+)-Norepinephrine 110 000 
(-)-isoproterenol 150 000 
Phentofamine 50 
Phenoxyben~amine 90 
(-)-Propranolol 100 000 
Ergotamine 7 
Dopsmine so 000 
Serotonine 150 000 
The experimental conditions used are those in fig.4. Apparent 
dissociation constants, Kd, were calculated according to the 
equation in [ 131 as in section 2. The Kd values for the 
(+)- and (-)“st~reoisomers of epinephrine and norep~ephr~e 
and for (-)-isoproterenot were calculated from the data in 
fig.4 
alkaloid ergotamine was, among ail the compounds 
tested in this study, the most efficient competitor 
(Kd 7 nM) (table 1). 
4. Discussion 
Although the existence of a-adrenergic receptors 
has been postulated in human and hamster adipocytes 
for over 5 years [2,4J, information about the recep- 
tors could only be inferred from pllysio~og~cal studies 
on the ability of various agents to stimulate or block 
the effects of cu-adrenergic agonists on cyclic AMP 
synthesis or on hpolysis [2,4,10,17,20]. 
Recently, binding methods using as a ligand either 
the cY-adrenergic antagonist [3H]dihydroergocryptine 
or the ~-adrenergic agonists f3H] cionidine and 
[3H]norepil~epllrine with high specific radioactivity 
have been successfully developed to specifically 
identify uterine smooth muscle- [6,7], platelets- [9], 
brain- [8,2 1. ] and liver-binding sites [22] which 
satisfy ati the criteria expected of physiologicat 
cu-adrenergic receptors. 
As presently shown. application of these methods 
to hamster adipocyte membranes has allowed for the 
first time the identification of [3H] dihydroergo- 
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cryptine binding sites which have also the character- 
istics expected of physiological cu-adrenergic recep- 
tors. 
In fact, binding of [3H]dihydroergocryptine was 
rapid with a time-course compatible with the rapid 
rate at which cr-adrenolytic agents enhance, in vitro, 
the stimulating effect of norepinephrine on the pro- 
duction of cyclic AMP by intact hamster adipocytes 
[IO]. Binding of [3H] dihydroergocryptine to hamster 
adipocyte membranes was also saturable, of high 
affinity and reversible. On the other hand, it was 
specific, the order of potency with which adrenergic 
agonists competed for the binding sites being iden- 
tical with that reported for a-adrenergic receptors in 
other cells [6-9,2 l-241 and opposite to the order of 
potency with which these compounds stimulate both 
cyclic AMP synthesis and lipolysis in hamster fat cells 
[17,19]. Moreover, the potent a-adrenolytic drugs, 
phentolamine and phenoxybenzamine [25], had high 
affinity for the binding sites, whereas propranolol, a 
/3-adrenolytic agent [25], exhibited a weak inhibition 
of [3H] dihydroergocryptine binding. Finally, the 
[3H]dihydroergocryptine binding sites of hamster 
adipocyte membranes are stereospecific and have a 
specificity pattern somewhat different from that 
found in rat brain cortex, in which binding appears to 
involve, besides the true a-adrenergic receptors, the 
dopamine and the serotonin receptors as well [26,27]. 
Experiments using other a-adrenergic antagonists 
(e.g., prazosin, yohimbine, indoramin) are currently 
under investigation in order to determine whether the 
dihydroergocryptine binding sites of hamster fat cells 
represent-one homogenous- or two different 
ol-adrenergic receptor-populations (or and 02) as 
recently reported for the rat brain cortex a-receptors 
[28,29]. 
The results of this direct binding study provide a 
more accurate and quantitative assessment of the 
action of cu-adrenolytic agents at the adipocyte 
a-adrenergic receptor sites than has been provided 
by the results of experiments such as those inves- 
tigating the modification of cyclic AMP level [4,10] 
and lipolysis [ lo,1 71. Furthermore, the present data 
may provide a tool for future studies on the molecular 
mechanisms of a-receptor-mediated adrenergic 
stimulation in adipocyte and especially those con- 
cerning the adrenergic control of lipolysis in human 
fat cells. In fact, while the regulation of the cyclic 
AMP level via the P-receptor adenylate cyclase system 
is well described, very little is known about the 
primary effects linked to the binding of catecholamines 
to a-receptors. Among these effects is the possible 
coupling of adipocyte a-receptors to processes 
regulating the transfer of calcium as recently suggested 
for the a-adrenergic receptors of other tissues [30,3 11. 
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